Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Boceprevir with peginterferon alfa-2b/ribavirin in treatment-naive chronic hepatitis C genotype 1: erythropoietin versus ribavirin dose reduction for anemia
2009-012782-63Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2009
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of boceprevir, peginterferon alfa-2b, ribavirin and epoetin alfa in hepatitis C virus infection (2 arms), sponsored by Merck & Co. Started Nov 2009; status: completed.
02
Drugs
boceprevirpeginterferon alfa-2bribavirinepoetin alfa
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2009-012782-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012782-63.